Spinal fluid sits at the center of this dementia and brain health question.

A new spinal fluid test has emerged as a game-changer for accurately distinguishing Parkinson’s disease from Alzheimer’s disease and other dementias. Researchers at the University Medical Center Amsterdam have identified a biological marker called DOPA decarboxylase—an enzyme that the brain uses to produce dopamine—which appears at significantly higher concentrations in the cerebrospinal fluid of people with Parkinson’s disease and Lewy body dementia. This discovery, published in Nature Medicine in 2026, offers the potential to end years of diagnostic uncertainty for patients whose symptoms initially seem to overlap between these neurological conditions.

The test is highly specific for Parkinson’s and Lewy body dementia, making it substantially different from the biomarkers associated with Alzheimer’s disease, which currently dominate diagnostic approaches. Why does this matter? Misdiagnosis between these conditions carries real clinical consequences. A patient with Lewy body dementia who is mistakenly treated as if they have Alzheimer’s or Parkinson’s disease alone may receive medications that actually worsen their condition—a risk that has affected countless families navigating the healthcare system. This article explores what the test reveals, how it works, why accurate diagnosis matters, and what patients and caregivers should know about this emerging diagnostic tool.

How Does the Spinal Fluid Biomarker Differentiate These Diseases?
Understanding Lewy Body Dementia and Why Misdiagnosis Happens
The Research Behind the Discovery
What Does a Diagnosis Mean for Treatment Decisions?
Limitations of the Spinal Fluid Test
When Should Patients Consider This Test?
The Broader Future of Dementia Diagnosis
Conclusion

How Does the Spinal Fluid Biomarker Differentiate These Diseases?

The key finding is striking: DOPA decarboxylase concentrations in cerebrospinal fluid are up to 2.5 times higher in patients with Parkinson’s disease or Lewy body dementia compared to healthy controls. This dramatic difference provides a biological fingerprint that reflects fundamental differences in how these diseases attack the brain. Parkinson’s disease primarily damages dopamine-producing neurons in a specific brain region called the substantia nigra, which explains why DOPA decarboxylase—the enzyme that manufactures dopamine—becomes more prominent in the spinal fluid. In contrast, Alzheimer’s disease damages brain cells more globally and develops through a different pathological mechanism involving amyloid and tau proteins, which produce distinct biomarker patterns.

The distinction is clinically powerful because it addresses one of neurology’s most frustrating diagnostic challenges: overlapping symptoms. A 68-year-old patient with tremor, slowness, and cognitive decline might fit the description of Parkinson’s disease, Lewy body dementia, or even Alzheimer’s disease. Before this test, neurologists relied on clinical judgment and months of observation to distinguish between these conditions. The DOPA decarboxylase marker cuts through that ambiguity by identifying the specific biological signature of Parkinson’s and Lewy body dementia, even when the clinical presentation is unclear.

How Does the Spinal Fluid Biomarker Differentiate These Diseases?

Understanding Lewy Body Dementia and Why Misdiagnosis Happens

Lewy body dementia deserves special attention because it is profoundly misdiagnosed. This condition, which affects cognitive function, movement, and behavior, occupies an uncomfortable middle ground between Parkinson’s disease and Alzheimer’s disease. Many patients are initially diagnosed with one of these conditions before the true diagnosis emerges. However, if you receive a Lewy body dementia diagnosis but are treated only for Parkinson’s disease, you may miss critical management strategies for the cognitive symptoms.

Worse, some antipsychotic medications commonly given for behavioral symptoms in Alzheimer’s can cause severe, even dangerous reactions in Lewy body dementia patients. The DOPA decarboxylase test helps resolve this diagnostic confusion by providing an objective biological marker. A patient showing elevated cerebrospinal fluid DOPA decarboxylase levels is far more likely to have Parkinson’s disease or Lewy body dementia than Alzheimer’s disease. This distinction is essential because the three conditions, while sharing some features like cognitive decline and movement problems, require different treatment approaches. The test is not perfect—no single biomarker can replace comprehensive clinical evaluation—but it provides a crucial piece of biological evidence that can guide diagnosis when symptoms are ambiguous.

The Research Behind the Discovery

This breakthrough comes from research led by Dr. Katharina Bolsewig and Professor Charlotte Teunissen at the University Medical Center Amsterdam, with contributions from Professor Sebastiaan Engelborghs in Belgium. These researchers analyzed cerebrospinal fluid samples from patients with various neurodegenerative conditions, comparing those with Parkinson’s disease, Lewy body dementia, Alzheimer’s disease, and healthy controls. The DOPA decarboxylase marker emerged as the most reliably elevated in Parkinson’s and Lewy body dementia, while remaining at normal or near-normal levels in Alzheimer’s patients and healthy individuals.

The choice of DOPA decarboxylase as a focus of study reflects a fundamental insight: the enzyme that manufactures dopamine in the brain becomes elevated in cerebrospinal fluid when dopamine-producing neurons are under stress or degenerating. This is not coincidence but biology. In Parkinson’s disease and Lewy body dementia, these neurons are the primary targets of the disease process, making the enzyme a natural biomarker. The fact that this single marker can differentiate these conditions so effectively underscores how differently these diseases attack the brain at the molecular level.

What Does a Diagnosis Mean for Treatment Decisions?

Accurate diagnosis directly determines treatment strategy. A patient confirmed to have Parkinson’s disease through the spinal fluid test benefits from dopamine replacement therapies like levodopa, which are central to Parkinson’s management. A patient with Lewy body dementia requires a more cautious approach: dopamine therapies may help movement symptoms, but behavioral and cognitive symptoms often demand careful medication choices. An Alzheimer’s disease patient, by contrast, benefits from disease-modifying treatments like amyloid-targeting monoclonal antibodies that are ineffective in Parkinson’s or Lewy body dementia.

The practical value emerges in daily decisions. Consider a 72-year-old woman with memory loss, confusion, and a tremor. If she is misdiagnosed with Alzheimer’s and started on an antipsychotic for behavioral symptoms, she may experience severe worsening—a known risk in Lewy body dementia. If the spinal fluid test shows elevated DOPA decarboxylase, her neurologist knows to pursue a Lewy body dementia workup instead, avoiding that harmful medication while implementing a treatment plan tailored to her actual condition. Early, accurate diagnosis also allows caregivers to prepare for the expected disease progression, which differs substantially across these three conditions.

Limitations of the Spinal Fluid Test

No diagnostic tool is universally perfect, and the DOPA decarboxylase test carries important limitations. The test requires a lumbar puncture, a procedure that, while generally safe, carries small risks of infection, headache, and bleeding. Not all patients can or will tolerate the procedure, particularly those who are elderly or have certain medical conditions. Additionally, while the test is highly specific for Parkinson’s and Lewy body dementia, it cannot distinguish between Parkinson’s disease itself and Lewy body dementia—both conditions show elevated DOPA decarboxylase.

Other clinical features and, often, the disease’s progression pattern must clarify this distinction. Furthermore, early-stage disease or rare variants may not show the expected marker elevations, potentially leading to a “false negative” result in a small percentage of cases. The test should be understood as one piece of diagnostic evidence, not a replacement for careful clinical evaluation, imaging, and patient history. Insurance coverage and test availability may also be barriers in some regions or healthcare systems. A neurologist interpreting the test result must integrate it with the patient’s symptoms, neurological examination, imaging findings, and response to treatment over time.

When Should Patients Consider This Test?

The spinal fluid test makes most sense for patients whose symptoms and presentation are unclear—those caught between diagnostic categories. If someone presents with progressive memory loss and no movement symptoms, the clinical picture points clearly toward Alzheimer’s, and the DOPA decarboxylase test may not be necessary. However, a patient with both cognitive symptoms and movement problems, or one who has received conflicting diagnoses, is an ideal candidate.

Similarly, a patient already diagnosed with Parkinson’s disease who develops significant cognitive problems might benefit from testing to clarify whether Lewy body dementia has emerged. Patients and families should discuss with a neurologist whether spinal fluid testing aligns with their diagnostic journey. In academic medical centers and specialized neurology clinics, this test is increasingly available, but it may not yet be routine in all settings. The test is most valuable when performed relatively early in the disease course, before years of treatment directed at the wrong diagnosis have obscured the clinical picture.

The Broader Future of Dementia Diagnosis

The DOPA decarboxylase discovery represents a shift toward biological, precision-based diagnosis in neurodegenerative disease. Rather than relying on clinical features alone—which can overlap and confuse—modern diagnosis increasingly relies on objective biomarkers from blood, spinal fluid, or imaging. This trend allows earlier detection, more accurate prognosis, and treatments tailored to the specific disease biology.

As research continues, additional biomarkers for other conditions will likely emerge, creating a more complete diagnostic toolkit for neurologists. Looking forward, some researchers are investigating blood-based biomarkers that might detect DOPA decarboxylase or related markers without requiring a lumbar puncture. Such advances could make accurate, early diagnosis accessible to more patients. In the meantime, the spinal fluid test offers a scientifically rigorous way to resolve diagnostic uncertainty in a population that has waited too long for clarity.

Conclusion

The identification of DOPA decarboxylase as a biomarker capable of differentiating Parkinson’s disease and Lewy body dementia from Alzheimer’s disease represents genuine progress in neurology. With cerebrospinal fluid levels up to 2.5 times higher in Parkinson’s and Lewy body dementia patients, the test provides an objective biological answer to a question that has historically relied on clinical guesswork. For patients and families caught in diagnostic uncertainty, this test offers the possibility of clarity and, crucially, the chance to avoid misguided treatments that could worsen their condition.

If you or a loved one faces ambiguous symptoms that could fit multiple neurodegenerative diagnoses, discussing spinal fluid biomarker testing with a neurologist is worthwhile. Early, accurate diagnosis enables appropriate treatment, allows caregivers to understand what lies ahead, and reduces the risk of harmful medication side effects. As neuroscience advances, precision diagnosis becomes the standard, and this test exemplifies how biological insights translate into better patient care.